CA3261000A1 - PYRIDO[4,3-D]PYRIMIDINES COMPOUNDS - Google Patents
PYRIDO[4,3-D]PYRIMIDINES COMPOUNDSInfo
- Publication number
- CA3261000A1 CA3261000A1 CA3261000A CA3261000A CA3261000A1 CA 3261000 A1 CA3261000 A1 CA 3261000A1 CA 3261000 A CA3261000 A CA 3261000A CA 3261000 A CA3261000 A CA 3261000A CA 3261000 A1 CA3261000 A1 CA 3261000A1
- Authority
- CA
- Canada
- Prior art keywords
- pyrido
- pyrimidine compounds
- pyrimidine
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263358324P | 2022-07-05 | 2022-07-05 | |
| US63/358,324 | 2022-07-05 | ||
| US202263394338P | 2022-08-02 | 2022-08-02 | |
| US63/394,338 | 2022-08-02 | ||
| US202263414939P | 2022-10-11 | 2022-10-11 | |
| US63/414,939 | 2022-10-11 | ||
| US202363502931P | 2023-05-18 | 2023-05-18 | |
| US63/502,931 | 2023-05-18 | ||
| PCT/IB2023/056844 WO2024009191A1 (en) | 2022-07-05 | 2023-06-30 | Pyrido[4,3-d]pyrimidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3261000A1 true CA3261000A1 (en) | 2024-01-11 |
Family
ID=87426656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3261000A Pending CA3261000A1 (en) | 2022-07-05 | 2023-06-30 | PYRIDO[4,3-D]PYRIMIDINES COMPOUNDS |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP4551296A1 (enExample) |
| JP (1) | JP2025525406A (enExample) |
| KR (1) | KR20250029954A (enExample) |
| CN (1) | CN119585286A (enExample) |
| AU (1) | AU2023302139A1 (enExample) |
| CA (1) | CA3261000A1 (enExample) |
| CL (1) | CL2024003699A1 (enExample) |
| CO (1) | CO2024016875A2 (enExample) |
| CR (1) | CR20240556A (enExample) |
| DO (1) | DOP2024000275A (enExample) |
| IL (1) | IL317957A (enExample) |
| MA (1) | MA71388A (enExample) |
| MX (1) | MX2024015001A (enExample) |
| PE (1) | PE20250259A1 (enExample) |
| TW (2) | TW202513571A (enExample) |
| WO (1) | WO2024009191A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3158793A1 (en) | 2019-10-28 | 2021-05-06 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
| US12479834B2 (en) | 2019-11-29 | 2025-11-25 | Taiho Pharmaceutical Co., Ltd. | Phenol compound or salt thereof |
| CN118302162A (zh) * | 2021-11-24 | 2024-07-05 | 默沙东有限责任公司 | Kras突变蛋白的小分子抑制剂 |
| AU2023231139A1 (en) | 2022-03-11 | 2024-09-05 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| CN119731180A (zh) | 2022-08-05 | 2025-03-28 | 金橘生物科技公司 | 杂环化合物及其用途 |
| TW202434606A (zh) * | 2022-11-17 | 2024-09-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合三環類化合物、其製備方法及其在醫藥上的應用 |
| EP4655073A2 (en) | 2023-01-26 | 2025-12-03 | Arvinas Operations, Inc. | Cereblon-based kras degrading protacs ans uses related thereto |
| WO2024178304A1 (en) * | 2023-02-24 | 2024-08-29 | Alterome Therapeutics, Inc. | Kras modulators |
| KR20250164828A (ko) | 2023-03-30 | 2025-11-25 | 레볼루션 메디슨즈, 인크. | Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도 |
| AU2024253142A1 (en) * | 2023-04-05 | 2025-10-16 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| WO2024218686A1 (en) * | 2023-04-20 | 2024-10-24 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| CN121194980A (zh) * | 2023-05-16 | 2025-12-23 | 和记黄埔医药（上海）有限公司 | 三环类化合物及其用途 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025085748A1 (en) | 2023-10-20 | 2025-04-24 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| WO2025130912A1 (zh) * | 2023-12-19 | 2025-06-26 | 正大天晴药业集团股份有限公司 | 三并环类化合物及其医药用途 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| CN119874616B (zh) * | 2025-03-28 | 2025-05-30 | 四川美域高生物医药科技有限公司 | 一种有机中间体及其制备方法和应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| ES2425269T3 (es) | 2007-12-14 | 2013-10-14 | Bristol-Myers Squibb Company | Moléculas de unión al receptor OX40 humano |
| SA112330278B1 (ar) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
| RU2638552C2 (ru) | 2011-09-27 | 2017-12-14 | Ф. Хоффманн-Ля Рош Аг | Пиразол-4-ил-гетероциклил-карбоксамидные соединения и способы применения |
| SA112330989B1 (ar) | 2011-11-17 | 2015-07-07 | فايزر انك | ببتيدات سامة للخلايا ومواد اقتران جسم مضاد وعقار منها |
| EP3164417A1 (en) | 2014-07-01 | 2017-05-10 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
| TWI703159B (zh) | 2015-04-13 | 2020-09-01 | 美商輝瑞股份有限公司 | Bcma特異性治療性抗體及其用途 |
| CN109563081A (zh) | 2016-04-07 | 2019-04-02 | 葛兰素史克知识产权开发有限公司 | 可用作蛋白调节剂的杂环酰胺类 |
| SI3440076T1 (sl) | 2016-04-07 | 2022-09-30 | Glaxosmithkline Intellectual Property Development Limited | Heterociklični amidi uporabni kot proteinski modulatorji |
| KR102356241B1 (ko) | 2016-11-16 | 2022-01-28 | 윙크 로보틱스, 인코포레이티드 | 미용 로보틱스용 변형 가능한 엔드 이펙터 |
| TW201906848A (zh) * | 2017-05-11 | 2019-02-16 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| EP3630835A1 (en) | 2017-05-31 | 2020-04-08 | STCube & Co., Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
| CN118772278A (zh) | 2017-06-02 | 2024-10-15 | 辉瑞公司 | Flt3的特异性抗体及其用途 |
| US11285131B2 (en) | 2017-08-04 | 2022-03-29 | Merck Sharp & Dohme Corp. | Benzo[b]thiophene STING agonists for cancer treatment |
| KR20220012255A (ko) * | 2019-04-28 | 2022-02-03 | 젠플리트 테라퓨틱스 (상하이) 아이엔씨. | 옥사아자퀴나졸린-7(8h)-케톤 화합물, 이의 제조 방법 및 이의 약학적 응용 |
| WO2021041671A1 (en) | 2019-08-29 | 2021-03-04 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| CN113980032B (zh) * | 2020-07-27 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 稠合四环类衍生物、其制备方法及其在医药上的应用 |
| EP4262807A4 (en) * | 2020-12-15 | 2025-04-23 | Mirati Therapeutics, Inc. | Azachinazoline pan-KRAS inhibitors |
| CN117083281A (zh) * | 2021-03-24 | 2023-11-17 | 南京明德新药研发有限公司 | 嘧啶并杂环类化合物及其应用 |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| CN118019746A (zh) * | 2021-09-27 | 2024-05-10 | 北京加科思新药研发有限公司 | 多环稠环衍生物及其用途 |
-
2023
- 2023-06-30 CR CR20240556A patent/CR20240556A/es unknown
- 2023-06-30 KR KR1020257003513A patent/KR20250029954A/ko active Pending
- 2023-06-30 PE PE2024002870A patent/PE20250259A1/es unknown
- 2023-06-30 JP JP2024576355A patent/JP2025525406A/ja active Pending
- 2023-06-30 CN CN202380051793.7A patent/CN119585286A/zh active Pending
- 2023-06-30 CA CA3261000A patent/CA3261000A1/en active Pending
- 2023-06-30 IL IL317957A patent/IL317957A/en unknown
- 2023-06-30 MA MA71388A patent/MA71388A/fr unknown
- 2023-06-30 EP EP23744558.0A patent/EP4551296A1/en active Pending
- 2023-06-30 AU AU2023302139A patent/AU2023302139A1/en active Pending
- 2023-06-30 WO PCT/IB2023/056844 patent/WO2024009191A1/en not_active Ceased
- 2023-07-04 TW TW113147938A patent/TW202513571A/zh unknown
- 2023-07-04 TW TW112124839A patent/TWI869913B/zh active
-
2024
- 2024-12-02 CL CL2024003699A patent/CL2024003699A1/es unknown
- 2024-12-03 MX MX2024015001A patent/MX2024015001A/es unknown
- 2024-12-09 CO CONC2024/0016875A patent/CO2024016875A2/es unknown
- 2024-12-30 DO DO2024000275A patent/DOP2024000275A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024009191A1 (en) | 2024-01-11 |
| CR20240556A (es) | 2025-01-29 |
| CL2024003699A1 (es) | 2025-04-11 |
| JP2025525406A (ja) | 2025-08-05 |
| TWI869913B (zh) | 2025-01-11 |
| DOP2024000275A (es) | 2025-01-31 |
| IL317957A (en) | 2025-02-01 |
| KR20250029954A (ko) | 2025-03-05 |
| MX2024015001A (es) | 2025-01-09 |
| PE20250259A1 (es) | 2025-01-29 |
| TW202513571A (zh) | 2025-04-01 |
| CN119585286A (zh) | 2025-03-07 |
| MA71388A (fr) | 2025-04-30 |
| CO2024016875A2 (es) | 2024-12-19 |
| EP4551296A1 (en) | 2025-05-14 |
| AU2023302139A1 (en) | 2024-12-19 |
| TW202409047A (zh) | 2024-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3261000A1 (en) | PYRIDO[4,3-D]PYRIMIDINES COMPOUNDS | |
| IL323521A (en) | Pyrido[4,3-d]pyrimidine compounds | |
| IL175813A0 (en) | PYRIDO [2,3-d] PYRIMIDINE-2,4-DIAMINES AS PDE 2 INHIBITORS | |
| EP2142543B8 (en) | Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer | |
| EP2142544B8 (en) | Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer | |
| EP3925669A4 (en) | 7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE DERIVATIVE | |
| ZA200803173B (en) | Pyrazolo [4,3-d] Pyrimidin-5-yl) Derivative used as PDE5 Inhibitors | |
| IL289953A (en) | History of 4-(imidazo[a-2,1]pyridine-3-yl)-pyrimidine and its use in cancer | |
| EP4267581A4 (en) | SUBSTITUTED IMIDAZO[1,5-B PYRIDAZINE COMPOUNDS AS KINASE INHIBITORS AND THEIR USE | |
| HK40117290A (zh) | 吡啶并[4，3-d]嘧啶化合物 | |
| EP4175957A4 (en) | 2,3-DISUBSTITUTED PYRIDO[3,4-B!PYRAZINE-CONTAINING COMPOUNDS AS KINASE INHIBITORS | |
| HK40111145A (zh) | 吡啶并[1，2-a]嘧啶-4-酮衍生物 | |
| HK40067927A (en) | 2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds | |
| PL4021452T3 (pl) | Podstawione związki (7h-pirolo[2,3-d]pirymidyn-4-ylo)aminowe przydatne jako inhibitory jak1 | |
| HK40076628A (en) | Pyrido[3,2-d]pyrimidine compounds as immunomodulators | |
| HK40109573A (en) | Pyrido[4,3-d]pyrimidine compounds capable of inhibiting kras mutant proteins | |
| CA3270641A1 (en) | Triazole-substituted imidazo[1,2-a]pyrimidines as cgas inhibitors | |
| ZA202406459B (en) | Pyrido[1,2-a]pyrimidin-4-one derivatives | |
| HK40112450A (zh) | 吡唑并[3，4-d]嘧啶化合物的固体形式 | |
| HK40061557A (en) | Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia | |
| HK40117266A (en) | Solid forms of pyrazolo[3,4-d]pyrimidine compounds | |
| HK40101182A (zh) | 2,8-二氮杂螺[4.5]癸烷化合物 | |
| HK40115318A (en) | 7h-pyrrolo[2,3-d]pyrimidines and preparation as dyrk1a inhibitors | |
| HK40111150A (en) | 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides | |
| EP4347594A4 (en) | 2, 8-DIAZASPIRO[4.5 DECANE COMPOUNDS |